STATE OF THE ART AND FUTURE PERSPECTIVES OF ADVANCED THERAPY MEDICINAL PRODUCTS IN ITALY AND IN THE INTERNATIONAL ARENA

Dario Lidonnici¹, Virginia Ronco¹, Stefania Niedecker², Anna D’Ausilio³, Elena Paola Lanati²

¹MA Provider, Milano (MI) – Italy
²MAProvider, Lugano – Switzerland

OBJECTIVES

To draw the scenario of Advanced Therapy Medicinal Products (ATMPs), state of the art and future perspectives, comparing European Union (EU) and United States (US) and to extrapolate the role of Italy in terms of expertise and centres of excellence.

METHODS

Horizon scanning has been performed by analysing different sources: i) EU, US and Italian Official Journals (OJ); ii) the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Italian Medicines Agency (AIFA) websites; iii) clinicaltrials.gov.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EMA</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>FDA</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

RESULTS

Results can be divided into 3 parts: i) state of the art; ii) future perspectives and iii) Italian context. i)The ATMPs scenario is quite different in EU and the US: the definition of ATMPs is not univocal, but differs between EMA and FDA. Specifically, 9 ATMPs have been approved by EMA vs 16 approved by FDA, of which cord blood products (n=8) are considered ATMPs by FDA only. Only 3 ATMPs have been approved both by EMA and FDA. ii)Clinical trials screening has identified 135 Phase III and Phase II/III trials from June 2016 to November 2017, 22 of which (16%) have been already completed. Only 19% of these RCTs are on rare diseases. Furthermore, 5 ATMPs are currently under EMA evaluation. iii) Reimbursed ATMPs in EU have been developed and produced in Italy. Furthermore, 53 Italian centres have been involved in clinical trials on ATMPs and 15 cell factories have been set.

CONCLUSIONS

ATMPs number is expected to grow significantly in the very next future in EU as well as in the US. In this context, Italy can be play an interesting role for clinical expertise and for Italian experience on price and reimbursement process.